Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Growth and Neurodevelopment study of Genotropin in very young children born small for gestational age
2007-003949-32Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of somatropin in Short stature in children born small for gestational age and Small for gestational age (SGA) (2 arms), sponsored by Pfizer. Primary endpoint: Change from baseline in height SDS after 24 months of treatment. Started Oct 2007; status: completed.
02
Drugs
somatropin
03
Conditions
Short stature in children born small for gestational ageSmall for gestational age (SGA)
Beyond the preview
Go deeper on 2007-003949-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003949-32.